UK healthtech startup Nul raises $1M to support alcohol reduction efforts

2026-02-16 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Medical Devices & Health Technology, Clinical Care & Medical Practice, Public Health & Epidemiology · Depth: Fundamental Awareness, quick

Summary

UK healthtech startup Nul has secured $1 million in seed funding, led by dmg ventures and BYVP, with additional angel investor participation. This capital will facilitate Nul's full commercial launch in the UK, expand its clinical and product teams, scale customer acquisition efforts, and prepare for future international expansion, including into the US market. Nul's platform offers a supported alcohol reduction program combining clinical care, prescription medication like naltrexone to reduce cravings, and digital treatment pathways based on The Sinclair Method. The fully remote subscription service includes virtual consultations and ongoing clinical support, targeting individuals seeking to reduce alcohol consumption without immediate or complete abstinence. Since its UK test phase launch in summer 2025, Nul has onboarded over 120 paying customers, achieving an annualised revenue run rate exceeding £300,000.

Key takeaway

For entrepreneurs and investors evaluating opportunities in healthtech, Nul's successful seed funding and early traction demonstrate significant market demand for modernized alcohol reduction solutions. You should consider how telehealth platforms, integrating clinical care and prescription medication, can address gaps in traditional treatment models, particularly in areas with limited innovation. This approach offers a scalable and discreet service that resonates with consumers seeking flexible health interventions.

Key insights

Nul's telehealth platform offers a medication- and therapy-supported alcohol reduction program for individuals seeking to moderate consumption.

Principles

• Telehealth can modernize underserved healthcare categories.
• Evidence-based treatment should be accessible and discreet.

Method

Nul's program integrates naltrexone medication, virtual consultations, and digital guidance based on The Sinclair Method via a remote subscription service.

In practice

• Utilize naltrexone for alcohol craving reduction.
• Implement remote subscription models for healthcare delivery.

Topics

• Healthtech
• Alcohol Reduction
• Telehealth Platform
• Naltrexone
• Seed Funding

Best for: Investor, Entrepreneur, Business Analyst

Related on AIssential

• WellSync Reports Strong BoomRx Momentum with More Than $70-Million Annualized Run Rate — Integrated pharmaceutical technology platforms are crucial for scaling virtual care and addressing supply chain complexities.
• Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity — A health awakening is driving demand for peptides and advanced bio-interventions, emphasizing individual responsibility and future bio-communication.
• Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468] — Proactive health strategies, leveraging existing and AI-accelerated medicines, can drive a trillion-dollar public health revolution.
• Bridging the Rural Healthcare Gap: A Cascaded Edge-Cloud Architecture for Automated Retinal Screening — An edge-cloud cascade reduces cloud usage for DR screening while maintaining high diagnostic performance.
• 01Health secures $15M to scale specialist healthcare platform — 01Health's platform decentralizes specialist healthcare by empowering local clinics with integrated technology and AI.
• Efferon secures €2.5M to grow blood purification platform — Efferon's hemoadsorption devices provide a certified solution for sepsis and septic shock, including a first-in-Europe pediatric version.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.